+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Immunotherapy Drugs Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)

  • PDF Icon


  • 120 Pages
  • April 2021
  • Region: Global
  • Mordor Intelligence
  • ID: 5305876
UP TO OFF until Dec 31st 2023
The Immunotherapy Drugs Market was valued at USD 164.68 billion in 2020 and is expected to reach USD 276.51 billion by 2026, registering a CAGR of 8.41 % during the forecast period.

As per research studies, immunotherapies as an adjunct therapy in severe COVID-19 cases. Immunotherapies based on inflammatory cytokine neutralization, immunomodulation, and passive viral neutralization not only reduce inflammation, inflammation-associated lung damage, or viral load but could also prevent intensive care unit hospitalization and dependency on mechanical ventilation.

The impact of COVID-19 on the immunotherapy drugs market is positive because many companies currently focused on the development of immunotherapy-based drugs or vaccines for COVID-19. Currently, BioNTech SE in collaboration with Pfizer Inc., conducting a phase III clinical trial to assess the safety, tolerability, and immunogenicity of BNT162b2 against COVID-19 in healthy participants.

The major factors attributing to the growth of the immunotherapy drugs market are the rising adoption of targeted therapy over traditional therapy, emergence of biosimilars, rising prevalence of chronic diseases and lifestyle disorders, and rising demand for monoclonal antibodies.

Furthermore, factors such as growing research collaborations, increasing number of research laboratories, and growing direct and indirect investments in research and development (R&D) by pharmaceutical and biotechnology companies will also support the growth of the market in the coming years. For instance, in 2019, Gilead Sciences, Inc and Humanigen, Inc collaborated to jointly conduct a study of lenzilumab with YESCARTA in patients with relapsed or refractory diffuse large B-cell lymphoma.

Globally, there has been a continuous rise in the prevalence of several chronic diseases, which, in several cases, need immune-based therapies. Some of the major chronic diseases include cancer, kidney failure, autoimmune and inflammatory diseases, and heart diseases. For instance, as per Versus Arthritis, in 2019, it was estimated that over 18% of people who were above 45 year of age in England had osteoarthritis of the knee.

In addition, according to a research article by Matthew Gowshall et al., published in International Journal of General medicine 2018, mortality from many non-communicable diseases (NCDs) or chronic diseases continues to increase worldwide, with a disproportionately larger impact in low-middle income countries (LMIs), with almost 75% of global deaths occur from chronic diseases. Several lifestyle disorders, both chronic and non-communicable diseases, such as hypertension, diabetes, obesity, and depression, need critical care during hospitalization.

For instance, according to the GLOBOCAN 2020 data, globally, in 2020, the total number of new cancer cases was found to be 9,227,484 indicating that it has risen to 19.3 million cases and 10 million cancer deaths in 2020. Lung cancer and prostate cancer are the most common among men, together accounting for nearly one-third of all male cancers.

The current trends of nanotechnology in immunotherapy will boost the market growth. The nanoparticles which are having dimensions of less than 100 nanometers have been engineered to treat cancer. The benefits provided are active or passive attack of drugs, high solubility bioavailability, and multifunctionality.

Overall, the rising R&D activities in the development of novel immunotherapies for various chronic diseases is anticipated to drive the global immunotherapy drugs market’s growth.

Key Market Trends

Cancer is Expected to Hold Significant Market Share in the Therapy Area Segment Over the Forecast Period
  • Cancer is an abnormal growth of the cells in the body. There are more than 100 different types of cancer. According to the GLOBOCAN data, in 2020, there were around 2,261,419 (11.7%) new breast cancer cases, 2,206,771 (11.4%) new lung cancer cases and 1,931,590 (10%) new colorectum cancer cases. Breast cancer represents 1 in 4 cancers diagnosed among women globally. Colorectal, lung, cervical, and thyroid cancers are also common among women. This cancer incidence is expected to rise in the coming years, which is helping the market to grow.
  • There are several types of immunotherapies used for the treatment of cancer. Some of the immunotherapies include immune checkpoint inhibitors, T-cells cell transfer, cancer vaccines, and immune system modulators. These therapies are used for many types of cancer and their advanced stages. Some of the popular immunotherapy drugs are Rituxan, Yervoy, Adcetris, and Zevalin, among several others.​
  • The market playera are launching new proucts for the treatmnent of cancer which is expected to boost the market growth. For instance, in July 2019, Amgen Inc and Allergan Plc launched MVASI (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), and KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin (trastuzumab) in the United States. MVASI, the first oncology therapeutic biosimilar approved by the U.S. Food and Drug Administration (FDA) for the treatment of five types of cancers such as metastatic colorectal cancer, non-squamous non-small cell lung cancer, renal cell carcinoma and others.
  • The growth of immunotherapies in developed markets is high, due to increased R&D, with better government policies for supporting clinical trials through findings and campaigns, in order to raise awareness regarding several kinds of cancer. For instance, according to the National Clinical Trial (NCT) Registry, Novartis Pharmaceuticals is conducting a phase Ib, open label, dose escalation study of spartalizumab plus LAG525 in combination with NIR178, capmatinib, MCS110, or canakinumab, followed by a dose expansion in adult patients with advanced or metastatic triple negative breast cancer (TNBC). The trial Started in January 2019 and expected to complete in January 2022.
  • Thus, owing to above mentioned factors it is expected to show significant growth over the forecast period.

North America Dominates the Market and is Expected to do Same in the Forecast Period

North America is expected to have a significant market share throughout the forecast period. This is due to the increasing incidence of cancers, rising geriatric population, growing preference, and adoption rate of immunotherapy rates across the region.

People with cancer are at higher risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-2-CoV) virus that causes COVID-19. Thus, researchers are in the development of effective therapeutics for COVID-19. For instance, Canadian Cancer Trials Group is conducting phase III clinical trial to find out if immunization with IMM-101 will reduce the incidence of severe respiratory and COVID-19 infections in cancer patients.

According to the estimates of the Globocan, in 2020, there were around 2,556,862 new cancer cases diagnosed and 699,274 deaths, due to cancer in the United States. The most common cancers in the United States are breast cancer, lung cancer, prostate cancer, colorectum cancer, bladder cancer, and skin cancer.​

According to the National Clinical Trial Registry (NCT) as of March 4, 2021, in United States, there are six interventional clinical trials across different phases of development to investigate the current coronavirus disease (COVID-19). This indicates researchers across United States, are underway in the development of vaccine or drug in the treatment of COVID-19 disease. This indicates the effectiveness of immunotherapy across different therapy areas which is expected to boost the market in near future.

In the North American region, the United States holds the largest market share. Factors, such as increased awareness among people for the early detection of diseases, better reimbursement policies, healthcare expenditure with better infrastructure, and increasing research and development activities and rising new product launches are the primary factors propelling the immunotherapy market in the United States. For instance, In May 2019, Humanigen, Inc., and Kite (Gilead Sciences, Inc.) collaborated to conduct a study of lenzilumab with YESCARTA in patients with relapsed or refractory diffuse large B-cell lymphoma.

In addition, in March 2019, Roche’s Tecentriq in combination with Abraxane received U.S.FDA accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer. Tecentriq combination is the first cancer immunotherapy regimen approved for breast cancer.Therefore, increasing research and development activities along rising burden of chronic diseases is expected to drive market growth over the forecast period.

Competitive Landscape

The immunotherapy drugs market is moderately fragmented and highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. The market players are focusing on new product launches R&D, expansions to gain a competitive advantage. In August 2019, U.S.FDA approved pexidartinib (TURALIO, Daiichi Sankyo) capsules for adult patients with symptomatic tenosynovial giant cell tumor (TGCT). Some of the major players of the market are AbbVie Inc., Amgen Inc., AstraZeneca, GlaxoSmithKline PLC, Novartis AG, and F. Hoffmann-La Roche AG, among others.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Adoption of Targeted Therapy over Traditional Therapy
4.2.2 Emergence of Biosimilars
4.2.3 Rising Prevalence of Chronic Diseases and Lifestyle Disorders
4.2.4 Rising Demand for Monoclonal Antibodies
4.3 Market Restraints
4.3.1 High Cost of Immunotherapy Treatment
4.3.2 High Attrition Rate in the Product Development Cycle
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Type of Drug
5.1.1 Monoclonal Antibodies
5.1.2 Vaccines
5.1.3 Interferons Alpha and Beta
5.1.4 Interleukins
5.1.5 Other Types of Drugs
5.2 By Therapy Area
5.2.1 Cancer
5.2.2 Autoimmune and Inflammatory Diseases
5.2.3 Infectious Diseases
5.2.4 Other Therapy Areas
5.3 Geography
5.3.1 North America United States (By Type of Drugs and By Therapy Area) Canada (By Type of Drugs and By Therapy Area) Mexico (By Type of Drugs and By Therapy Area)
5.3.2 Europe Germany (By Type of Drugs and By Therapy Area) United Kingdom (By Type of Drugs and By Therapy Area) France (By Type of Drugs and By Therapy Area) Italy (By Type of Drugs and By Therapy Area) Spain (By Type of Drugs and By Therapy Area) Rest of Europe (By Type of Drugs and By Therapy Area)
5.3.3 Asia-Pacific China (By Type of Drugs and By Therapy Area) Japan (By Type of Drugs and By Therapy Area) India (By Type of Drugs and By Therapy Area) Australia (By Type of Drugs and By Therapy Area) South Korea (By Type of Drugs and By Therapy Area) Rest of Asia-Pacific (By Type of Drugs and By Therapy Area)
5.3.4 Middle East and Africa GCC (By Type of Drugs and By Therapy Area) South Africa (By Type of Drugs and By Therapy Area) Rest of Middle East and Africa (By Type of Drugs and By Therapy Area)
5.3.5 South America Brazil (By Type of Drugs and By Therapy Area) Argentina (By Type of Drugs and By Therapy Area) Rest of South America (By Type of Drugs and By Therapy Area)
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Amgen Inc.
6.1.3 AstraZeneca plc
6.1.4 Bristol-Myers Squibb
6.1.5 F. Hoffmann-La Roche AG
6.1.6 GlaxoSmithKline plc
6.1.7 Johnson & Johnson
6.1.8 Merck & Co. Inc.
6.1.9 Novartis AG
6.1.10 UbiVac
6.1.11 Pfizer Inc
6.1.12 Bayer AG
6.1.13 Sanofi
6.1.14 Boehringer Ingelheim
6.1.15 Gilead Sciences, Inc

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • UbiVac
  • Pfizer Inc
  • Bayer AG
  • Sanofi
  • Boehringer Ingelheim
  • Gilead Sciences, Inc